13.76 USD
▲+0.05+5.44%
2026-08-03
市值
$10.98B
市盈率
—
EPS
-1.12
股息率
—
52 周区间
12.25 – 30.98
成交量
4.00M
Beta
-1.23
目标价
28.36
52W 低 12.2552W 高 30.98
价格走势
公司简介
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto...